Neos Therapeutics Resubmits NDA for FDA Review of Amphetamine Extended-Release Orally Disintegrating Tablets to Treat ADHD

By: via Benzinga
Neos Therapeutics, Inc. (NASDAQ: NEOS today announced that it has resubmitted a New Drug Application ("NDA") to the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.